Logo image of 4AB.DE

ABBVIE INC (4AB.DE) Stock Price, Quote, News and Overview

FRA:4AB - Deutsche Boerse Ag - US00287Y1091 - Common Stock - Currency: EUR

196.38  +2.18 (+1.12%)

4AB.DE Quote, Performance and Key Statistics

ABBVIE INC

FRA:4AB (3/7/2025, 7:00:00 PM)

196.38

+2.18 (+1.12%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High204.45
52 Week Low141.98
Market Cap346.68B
Shares1.77B
Float1.76B
Yearly Dividend5.75
Dividend Yield3.11%
PE21.07
Fwd PE17.02
Earnings (Next)04-24 2025-04-24/bmo
IPO01-02 2013-01-02


4AB.DE short term performance overview.The bars show the price performance of 4AB.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15

4AB.DE long term performance overview.The bars show the price performance of 4AB.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of 4AB.DE is 196.38 EUR. In the past month the price increased by 5.49%. In the past year, price increased by 18.59%.

ABBVIE INC / 4AB Daily stock chart

4AB.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B
1MRNA.MI MODERNA INC N/A 12.34B

About 4AB.DE

Company Profile

4AB logo image AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. The company offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The company also offers CEL383 for the treatment of inflammatory bowel disease.

Company Info

ABBVIE INC

1 N Waukegan Rd

North Chicago ILLINOIS US

Employees: 50000

Company Website: https://www.abbvie.com/

Investor Relations: https://investors.abbvie.com

Phone: 18479327900

ABBVIE INC / 4AB.DE FAQ

What is the stock price of ABBVIE INC today?

The current stock price of 4AB.DE is 196.38 EUR. The price increased by 1.12% in the last trading session.


What is the ticker symbol for ABBVIE INC stock?

The exchange symbol of ABBVIE INC is 4AB and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is 4AB.DE stock listed?

4AB.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for ABBVIE INC stock?

33 analysts have analysed 4AB.DE and the average price target is 200.78 EUR. This implies a price increase of 2.24% is expected in the next year compared to the current price of 196.38. Check the ABBVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABBVIE INC worth?

ABBVIE INC (4AB.DE) has a market capitalization of 346.68B EUR. This makes 4AB.DE a Mega Cap stock.


How many employees does ABBVIE INC have?

ABBVIE INC (4AB.DE) currently has 50000 employees.


What are the support and resistance levels for ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a support level at 196.37. Check the full technical report for a detailed analysis of 4AB.DE support and resistance levels.


Is ABBVIE INC (4AB.DE) expected to grow?

The Revenue of ABBVIE INC (4AB.DE) is expected to grow by 6.13% in the next year. Check the estimates tab for more information on the 4AB.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABBVIE INC (4AB.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABBVIE INC (4AB.DE) stock pay dividends?

ABBVIE INC (4AB.DE) has a dividend yield of 3.11%. The yearly dividend amount is currently 5.75. Check the full fundamental report for a detailed analysis of 4AB.DE dividend history, reliability and sustainability.


When does ABBVIE INC (4AB.DE) report earnings?

ABBVIE INC (4AB.DE) will report earnings on 2025-04-24, before the market open.


What is the Price/Earnings (PE) ratio of ABBVIE INC (4AB.DE)?

The PE ratio for ABBVIE INC (4AB.DE) is 21.07. This is based on the reported non-GAAP earnings per share of 9.32 and the current share price of 196.38 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 4AB.DE.


4AB.DE Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE is one of the better performing stocks in the market, outperforming 88.57% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

4AB.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. While 4AB.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

4AB.DE Financial Highlights

Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 9.32. The EPS decreased by -8.91% compared to the year before.


Industry RankSector Rank
PM (TTM) 7.52%
ROA 3.14%
ROE 127.46%
Debt/Equity 18.15
Chartmill High Growth Momentum
EPS Q2Q%-22.58%
Sales Q2Q%5.6%
EPS 1Y (TTM)-8.91%
Revenue 1Y (TTM)3.71%

4AB.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to 4AB.DE. The Buy consensus is the average rating of analysts ratings from 33 analysts.

For the next year, analysts expect an EPS growth of 23.75% and a revenue growth 6.13% for 4AB.DE


Ownership
Inst Owners73.92%
Ins Owners0.07%
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price Target200.78 (2.24%)
EPS Next Y23.75%
Revenue Next Year6.13%